Name
Alnylam Pharmaceuticals
Company Description
Since its founding, Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Alnylam is headquartered in Cambridge, MA. For more information, visit www.alnylam.com.
Website
https://www.alnylam.com
Product Categories (5)
Biotechnology Pharmaceuticals, Market Research
Address
675 W. Kendall St
Cambridge, MA 02142
United States